文献速递炎症性肠病

儿童期与成人期发病炎症性肠病的差异:GETECCU的CAROUSEL研究

Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-13

基于ENEIDA登记库2007至2017年诊断的炎症性肠病患者,比较儿童期发病(≤16岁,846例)与成人期发病(>16岁,21 200例)的特征。儿童期发病者回结肠受累和炎症行为比例更高,调整混杂后免疫调节剂使用风险HR=1.2(95%CI 1.1-1.2)、生物制剂治疗概率HR=1.2(95%CI 1.1-1.3),但手术风险无升高(HR=0.9,95%CI 0.8-1.2)。

要点

  • 儿童期发病IBD诊断时回结肠受累及炎症行为比例高于成人期发病。
  • 儿童期发病者使用免疫调节剂风险HR=1.2(95%CI 1.1-1.2)。
  • 儿童期发病者接受生物制剂治疗概率HR=1.2(95%CI 1.1-1.3),手术风险HR=0.9(95%CI 0.8-1.2)。

核心结论

  • 儿童期发病IBD具有不同特征,且免疫调节剂和生物制剂治疗风险高于成人期发病,但儿童期IBD与手术风险升高无关。

研究设计与样本

  • 基于ENEIDA登记库的多中心队列研究,纳入2007至2017年诊断的IBD患者。
  • 儿童期发病队列为诊断时≤16岁者,共846例(4%)。
  • 成人期发病队列为诊断时>16岁者,共21 200例(96%)。
  • 采用Kaplan-Meier曲线估计累积发病率,log-rank检验比较,Cox回归分析预测因素。

主要发现

  • 儿童期发病队列中位随访54个月,成人期发病队列中位随访38个月(P < 0.01)。
  • 儿童期发病队列诊断时克罗恩病、回结肠受累和炎症行为的比例高于成人期发病队列。
  • 多变量分析调整性别、IBD类型、肠外表现、家族史和吸烟习惯后,儿童期发病IBD与免疫调节剂使用风险较高相关(HR=1.2,95%CI 1.1-1.2)。
  • 儿童期发病IBD与接受生物制剂治疗概率较高相关(HR=1.2,95%CI 1.1-1.3)。
  • 儿童期发病IBD与手术风险升高无关(HR=0.9,95%CI 0.8-1.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cohort studies comparing the characteristics of childhood-onset and adulthood-onset inflammatory bowel disease (IBD) in the biologics era are scarce. AIM: To compare disease characteristics, the use of immunomodulators and biologic agents and the need for surgery between childhood- and adulthood-onset IBD. METHODS: Inflammatory bowel disease patients from the ENEIDA registry diagnosed between 2007 and 2017 were included. The childhood-onset cohort comprised patients diagnosed at ≤16 years of age and the adulthood-onset cohort those diagnosed at >16 years. The cumulative incidences of immunosuppressive therapy, biologic therapy and surgery were estimated using Kaplan-Meier curves, compared by the log-rank test. Cox regression analysis was performed to identify potential predictive factors of treatment with immunosuppressants, biologic agents or surgery. RESULTS: The adulthood-onset cohort comprised 21 200 patients out of 20 354 (96%) and the childhood-onset cohort 846 (4%). Median follow-up was 54 months in the childhood-onset cohort and 38 months in the adulthood-onset cohort (P < 0.01). Proportions of Crohn's disease, ileocolonic involvement and inflammatory behaviour at diagnosis were higher in the childhood-onset cohort. In the multivariate analysis, after adjusting for sex, type of IBD, extraintestinal manifestations, family history and smoking habit, childhood-onset IBD was associated with higher risk of immunomodulator use (hazard ratio [HR] = 1.2, 95% confidence interval [95% CI] = 1.1-1.2) and higher probability of receiving biologic treatment (HR = 1.2, 95% CI = 1.1-1.3). However, childhood-onset IBD was not associated with higher risk of surgery (HR = 0.9, 95% CI = 0.8-1.2). CONCLUSIONS: Childhood-onset IBD has differential characteristics and higher risk of treatment with immunomodulators and biologic agents, compared with adulthood-onset IBD. Nevertheless, paediatric IBD is not associated with higher risk of surgery.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chaparro M, Garre A, Ricart E, et al. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther. 2019. PMID: 30637837. doi:10.1111/apt.15114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。